InvestorsHub Logo
Post# of 252467
Next 10
Followers 22
Posts 1671
Boards Moderated 0
Alias Born 12/12/2006

Re: researcher59 post# 156822

Monday, 02/11/2013 10:28:07 PM

Monday, February 11, 2013 10:28:07 PM

Post# of 252467
Agree..the institutions paid $25+ and they were oversubscribed ! SRPT is unlikely to go any lower than low 20's. A likely scenario is FDA may ask SRPT to do a controlled but short trial (aka expanded PI) in line with their new paradigm shift of supporting pathways for innovative drugs. Eteplirsen definitely qualifies in that regard.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.